Myriam Labopin Selected Research

Cell Transplantation

10/2022	Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT).
3/2022	20-Year Steady Increase in Survival of Adult Patients with Relapsed Philadelphia-Positive Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation.
1/2022	Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia.
1/2022	Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party.
1/2022	Impact of the Addition of Antithymocyte Globulin to Post-Transplantation Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood Compared to Post-Transplantation Cyclophosphamide Alone in Acute Myelogenous Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
1/2022	Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation.
1/2022	Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia Working Party of the EBMT.
10/2021	A multicentre, multinational, prospective, observational registry study of defibrotide in patients diagnosed with veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic cell transplantation: an EBMT study.
1/2021	Improved Outcomes of Haploidentical Hematopoietic Cell Transplantation with Total Body Irradiation-Based Myeloablative Conditioning in Acute Lymphoblastic Leukemia.
1/2021	Outcome of T-cell-replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Myriam Labopin Research Topics

Disease

160	Leukemia 10/2022 - 04/2002
144	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2022 - 11/2002
46	Graft vs Host Disease (Graft-Versus-Host Disease) 10/2022 - 02/2004
42	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 03/2022 - 02/2008
16	Neoplasms (Cancer) 03/2021 - 03/2015
13	Pathologic Complete Response 10/2022 - 11/2010
9	Autoimmune Diseases (Autoimmune Disease) 01/2021 - 02/2010
8	Hematologic Neoplasms (Hematological Malignancy) 08/2020 - 02/2006
7	Bronchiolitis Obliterans Syndrome 11/2021 - 05/2015
5	Residual Neoplasm 12/2020 - 09/2014
5	Chromosome Aberrations (Chromosome Abnormalities) 01/2020 - 07/2008
5	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 11/2019 - 09/2014
5	Crohn Disease (Crohn's Disease) 05/2019 - 12/2015
4	Hematologic Diseases (Blood Diseases) 01/2021 - 01/2017
3	Philadelphia Chromosome 01/2021 - 03/2015
3	Infections 01/2020 - 09/2015
3	Sickle Cell Anemia (Hemoglobin S Disease) 12/2019 - 01/2017
2	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 10/2021 - 01/2018
2	COVID-19 01/2021 - 01/2021
2	Systemic Scleroderma (Systemic Sclerosis) 01/2021 - 12/2017
2	Monosomy 01/2020 - 01/2018
2	monosomy Chromosome 7 01/2020 - 01/2018
2	Inflammation (Inflammations) 05/2019 - 01/2017
1	Cardiotoxicity 06/2021
1	Acute Promyelocytic Leukemia 01/2021
1	Diffuse Scleroderma (Progressive Systemic Sclerosis) 01/2021
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2021
1	Hyperbilirubinemia 12/2020
1	Malnutrition (Nutritional Deficiencies) 11/2020
1	Sarcoma (Soft Tissue Sarcoma) 10/2020
1	Multiple Sclerosis 01/2020
1	Bites and Stings (Sting) 01/2020
1	Bone Marrow Failure Disorders 01/2020
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2020
1	Cytopenia 01/2020
1	Toxoplasmosis 01/2020
1	Immune System Diseases (Immune Disorders) 10/2019
1	Arthralgia (Joint Pain) 01/2019
1	Arthritis (Polyarthritis) 01/2019
1	Hemorrhage 01/2018

Drug/Important Bio-Agent (IBA)

45	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2022 - 10/2013
24	Busulfan (Busulfex)FDA Link 01/2022 - 10/2013
19	fludarabineIBA 01/2022 - 04/2015
17	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 01/2022 - 05/2015
12	Thiotepa (Triethylenethiophosphoramide)FDA LinkGeneric 01/2022 - 01/2016
9	HLA Antigens (Human Leukocyte Antigens)IBA 01/2022 - 11/2008
6	treosulfanIBA 01/2022 - 07/2017
6	Melphalan (Alkeran)FDA LinkGeneric 01/2022 - 04/2015
5	Mycophenolic Acid (Cellcept)FDA LinkGeneric 01/2022 - 03/2016
5	Tyrosine Kinase InhibitorsIBA 01/2021 - 03/2015
5	Clofarabine (Clolar)FDA Link 08/2020 - 09/2012
4	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2022 - 07/2008
4	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2022 - 05/2015
4	Calcineurin InhibitorsIBA 01/2021 - 03/2016
4	Sorafenib (BAY 43-9006)FDA Link 03/2019 - 01/2018
3	AntigensIBA 01/2022 - 05/2019
3	Azacitidine (5 Azacytidine)FDA Link 01/2020 - 01/2016
3	SteroidsIBA 01/2017 - 04/2002
2	fms-Like Tyrosine Kinase 3IBA 01/2022 - 01/2020
2	Immunosuppressive Agents (Immunosuppressants)IBA 01/2022 - 12/2019
2	Methotrexate (Mexate)FDA LinkGeneric 01/2022 - 12/2020
2	defibrotideIBA 10/2021 - 01/2018
2	Gemtuzumab (Mylotarg)FDA Link 12/2020 - 01/2020
2	AntibodiesIBA 01/2020 - 02/2015
2	Etoposide (VP 16)FDA LinkGeneric 01/2020 - 01/2018
2	Interleukin-15 (Interleukin 15)IBA 04/2018 - 01/2018
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 04/2016 - 02/2004
1	Alkylating AgentsIBA 01/2022
1	Amsacrine (AMSA)IBA 01/2022
1	Core Binding Factor Alpha 2 SubunitIBA 10/2021
1	Transaminases (Aminotransferases)IBA 12/2020
1	Tacrolimus (Prograf)FDA LinkGeneric 10/2020
1	antineoplaston A10 (A 10)IBA 01/2020
1	Core Binding Factors (Core-Binding Factor)IBA 01/2020
1	Sulfamethoxazole Drug Combination Trimethoprim (Co-Trimoxazole)FDA LinkGeneric 01/2020
1	Rituximab (Mabthera)FDA Link 01/2020
1	Thymidine Monophosphate (TMP)IBA 01/2020
1	Phenobarbital (Luminal)FDA Link 05/2019
1	LigandsIBA 01/2019
1	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2019
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2018
1	Transcription Factors (Transcription Factor)IBA 01/2018
1	CohesinsIBA 01/2018
1	Polycomb Repressive Complex 2IBA 01/2018

Therapy/Procedure

151	Transplantation 10/2022 - 04/2002
115	Stem Cell Transplantation 10/2022 - 02/2003
74	Hematopoietic Stem Cell Transplantation 10/2022 - 11/2002
43	Cell Transplantation 10/2022 - 02/2015
31	Therapeutics 01/2021 - 04/2002
19	Haploidentical Transplantation 01/2022 - 04/2015
18	Drug Therapy (Chemotherapy) 01/2022 - 06/2008
12	Homologous Transplantation 01/2020 - 11/2002
11	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/2022 - 04/2002
7	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 10/2022 - 03/2015
4	Autologous Transplantation 12/2017 - 01/2005
1	Cord Blood Stem Cell Transplantation 10/2022
1	Traction 01/2021
1	Nutritional Support (Artificial Feeding) 11/2020
1	Donor Selection 11/2019
1	Biological Therapy 05/2019